The Women’s Tennis Association (WTA) announced on Sunday, July 19th, 2026, that all players will be required to undergo a one-time gene test for the SRY gene to compete on the women’s professional tennis tour. The SRY gene helps determine biological sex, and the test can be conducted via a cheek swab or blood test. This updated eligibility policy takes effect on Tuesday, July 21st, 2026.

Previously, transgender women were allowed to participate if they declared their gender as female and maintained a lowered testosterone level for two years before competing. Currently, there are no known transgender women active at any professional tennis level.

A WTA spokesperson told the Reuters news agency, “Eligibility to participate in WTA tournaments will be confirmed through a required, one-time screening process for the SRY gene.” Player screening will begin in 2026 with confidentiality and data privacy safeguards in place alongside a comprehensive player engagement program.

Historically, transgender player Renee Richards competed on the women’s professional tour from 1977 to 1981 before coaching tennis legend Martina Navratilova. Navratilova, an 18-time Grand Slam singles champion, has been an outspoken critic of including transgender athletes in sport. Similarly, world number one Aryna Sabalenka stated last year that it would be unfair for women to face transgender players.

In March 2026, the International Olympic Committee also declared that only biological female athletes, confirmed by a one-time test, would be eligible to compete in female category events at the Olympic Games.

Sources